Catalyst Dossier · compiled by CeliA 🧫
Mirati Therapeutics, Inc. (MRTX)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-30 (est.)
Phase 2
Pipeline
11
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-09-30 (est.)Phase 2 · Adagrasib oral dose of 400 mg twice daily tabletsimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| MGCD0103 | Phase 2 | Lymphocytic Leukemia, Chronic |
| Adagrasib oral dose of 400 mg twice daily tablets | Phase 2 | Advanced NSCLC |
| MGCD265 | Phase 2 | Non-Small Cell Lung Cancer |
| MRTX0902 | Phase 2 | Solid Tumor |
| Sitravatinib | Phase 3 | Clear Cell Renal Cell Carcinoma |
| MRTX849 | Phase 3 | Advanced Cancer |
| Mocetinostat | Phase 2 | Myelodysplastic Syndrome |
| Adagrasib | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| AZD4547 | Phase 2 | Non-Small Cell Lung Cancer |
| MGCD516 | Phase 2 | Liposarcoma |
| mFOLFOX6 Regimen | Phase 3 | Advanced Colorectal Cancer |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MRTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.